Industry
Healthcare Plans — Industry Primer
The "Healthcare Plans" industry is two very different businesses bolted into one ticker. One sells risk (insurers collect premiums, pay claims, earn the gap minus admin); the other sells scale and information (pharmacy benefit managers — PBMs — run drug claims and buy on behalf of plan sponsors). Both run on razor-thin 1–3% GAAP margins, depend on enormous gross dollars flowing through their ledgers, and reprice annually against rising medical cost trend. Because revenue is mostly pass-through, what matters is whether the medical care ratio (MCR) and PBM client retention are stable — not whether revenue grew.
1. Industry in One Page
The insurance + PBM slice is a low-margin distribution layer that exists because employers, governments, and individuals pay to outsource three jobs: negotiating prices with hospitals, doctors, and drugmakers; paying claims and arbitrating coverage; and bearing risk when claim costs are uncertain. Whoever holds the most members has the strongest leverage with providers; whoever processes the most prescription claims has the strongest position with drug manufacturers. Premium-to-claims ratios, network adequacy, formulary design, and PBM rebate practices are all governed by federal and state rules.
Takeaway. Cigna sits in seats #2 and #3. The fattest profit pools (pharma and hospitals) sit on either side, which is why "managing the cost trend" is industry shorthand for how much of someone else's pricing power can we claw back?
2. How This Industry Makes Money
Three distinct revenue mechanisms stack inside one company. The economics differ enough that they should be understood separately before being added together.
Revenue ratio is roughly 5-to-1 in Evernorth's favor; pre-tax margin is the inverse — Cigna Healthcare 8.8% vs Evernorth 3.1%. The PBM is a high-volume, low-margin scale machine; the insurer is a lower-volume, mid-margin underwriting book. Looking only at consolidated revenue misjudges which lever moves earnings.
Bargaining power matrix. PBMs hold leverage against drug manufacturers (formulary placement) and pharmacies (network access); insurers hold leverage against hospitals (in-network status) and members (plan design). Hospitals push back through consolidation; manufacturers push back through specialty pipelines they alone can produce. The squeeze on margins comes when either side accretes pricing power faster than the middleman can defend.
3. Demand, Supply, and the Cycle
Demand is mostly a function of who is employed, who is eligible, and what gets prescribed. Supply is bounded by provider networks and drug pipelines. The cycle that matters for stocks is the MCR cycle: a 12–24-month lag between when medical cost trend accelerates and when insurers can reprice premiums to catch up.
The 2023–2025 episode is the textbook case. Three forces hit at once: (a) Medicaid redeterminations after the COVID public-health emergency left a sicker remaining pool; (b) post-pandemic Medicare Advantage utilization caught up faster than insurers had priced; (c) GLP-1 weight-loss drugs created a brand-new line item of $10–15K per patient per year. Insurer MCRs ran 100–300 basis points hot, Medicare-only Humana saw earnings collapse, and Centene printed a full-year operating loss in FY2025. Cigna's commercial-and-PBM mix insulated it, but its own Cigna Healthcare MCR still climbed from 81.3% (2023) to 84.4% (2025).
4. Competitive Structure
Two overlapping competitive maps run inside this one industry. The managed-care insurer map is consolidated but multi-player; the PBM map is a near-monopoly held by three firms. Reading both is essential — Cigna is small in the first and #1 in the second.
Express Scripts is the only volume figure publicly reported (2.22B adjusted claims, +4.8% YoY); CVS Caremark and OptumRx volumes are illustrative relative positions consistent with the Big-3 share of roughly 80% of US equivalent claims.
The PBM market is a triopoly. The three firms above process roughly 80% of US equivalent prescription claims, and even smaller PBMs often rent claims processing, network management, and rebate negotiation from one of the Big Three. This is not a competitive market in any textbook sense — it is an oligopoly with regulatory scrutiny and very high switching costs.
The managed-care side looks more contestable: six listed firms plus the regional Blue Cross Blue Shield licensees (most large state Blues are not publicly traded). Per the AMA, 90% of metropolitan markets were "highly concentrated" in 2022, but national share is fragmented because the Blues hold the dominant local positions. In commercial employer ASO (self-funded), scale and network depth dominate; in Medicare Advantage, it is local star ratings and network; in Medicaid, it is RFP relationships with state agencies. Each sub-market has different economics and different competitive sets.
5. Regulation, Technology, and Rules of the Game
Every dollar of margin in this industry is held in place by a regulatory rule, and every rule change moves stocks. The five that matter most:
Two recent developments matter. First, the FTC insulin-pricing case settled February 4, 2026 under a 10-year monitored agreement with no monetary fines — the company calls it a "clearing event"; Bloomberg Law called the broader consent order "the most consequential structural overhaul of the PBM industry to date." Second, October 2025's Express Scripts rebate-free pharmacy model accelerates the structural shift from spread-and-rebate economics toward an explicit administrative fee. The 2026 Evernorth adjusted operating income guide of at least $6.9B is down from $7.2B in 2025 — a deliberate reinvestment to migrate the model.
6. The Metrics Professionals Watch
Forget gross margin. In this industry, the working metrics tell the whole story. Anyone reading a quarterly release should look for these eight numbers in this order.
The single most important number for an insurer is the MCR versus its own forward guidance. A 100bp miss on a $50B premium book is $500M of lost pre-tax income — enough to break a year of EPS guidance. For a PBM, the equivalent is adjusted Rx claim volume + retention rate — together they measure whether the scale flywheel is intact.
7. Where Cigna Group Fits
Cigna is unusual in this industry because it leads in PBM and lags in insurance. Its strategic choice in 2024–2025 — selling Medicare Advantage to HCSC and retaining a commercial-and-PBM book — explicitly tilted the company toward Evernorth and away from the senior-insurance utilization risk that has hurt Humana, CVS-Aetna, and UnitedHealth.
FY2025 Revenue ($M)
Customer Relationships (M)
Medical Customers (M)
Cigna Healthcare MCR
The picture is a PBM scale leader stapled to a focused commercial insurer. Unlike UnitedHealth (deeply vertically integrated through Optum's clinics) or CVS Health (built around a retail-pharmacy footprint), Cigna has chosen a "partner-first" model — selling its physical clinic assets and exiting Medicare to keep the asset base capital-light. That choice insulates near-term earnings from the senior-insurance utilization spike, but concentrates the equity story on whether the rebate-free PBM transition holds Express Scripts margins through 2026–2027.
8. What to Watch First
A reader who is tracking this name as the industry backdrop changes can monitor the points below. Each one is observable in filings, transcripts, federal notices, or trade publications without an expensive subscription.
The clearest near-term test is Q2-Q3 FY2026: did the Cigna Healthcare MCR start retreating from 84.4%, and did Evernorth adjusted operating income come in at or above the $6.9B floor management guided in February? Those two numbers together confirm whether the 2026 transition year is going to plan.